naa a22 4500 510763162 CHVBK 20180411083147.0 cr unu---uuuuu 180411e20130101xx s 000 0 eng 10.1007/s12094-012-0934-8 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0934-8 Analysis of economic evaluations of pharmacological cancer treatments in Spain between 1990 and 2010 [Elektronische Daten] [Ángel Sanz-Granda, Álvaro Hidalgo, Juan del Llano, Joan Rovira] Economic evaluation of pharmacological cancer treatment is a critical clinical problem currently under consideration worldwide. We have analysed their main characteristics in Spain between 1990 and 2010 following a systematic review of the 29 complete economic analyses published. The pathology most frequently evaluated was non-small cell lung cancer (31%). Cost-effectiveness analyses (69%) were the most frequent analyses. A wide range of incremental cost-effectiveness values (295-160,667 €/QALY) has been reported, and mostly are developed from the perspective of the National Health System (65.5%). However, none of the studies estimated the indirect costs. The major conclusion is that the absence of regulations concerning the application of the efficiency criterion in decision-making on the subject of price and financing and, most importantly, the fact that these are not included in Spanish hospitals forms make it difficult to analyse the real impact of economic evaluations of cancer treatments on such decisions. Federación de Sociedades Españolas de Oncología (FESEO), 2012 Economic evaluation nationallicence Cost-effectiveness nationallicence Medications nationallicence Drugs nationallicence Cancer/oncology nationallicence Spain nationallicence Sanz-Granda Ángel Weber Economía y Salud, Pharmacoeconomics Department, Madrid, Spain aut Hidalgo Álvaro Universidad de Castilla-La Mancha, Las Norias 123, Majadahonda, 28221, Madrid, Spain aut del Llano Juan Gaspar Casal Foundation, Madrid, Spain aut Rovira Joan Universidad de Barcelona, Barcelona, Spain aut Clinical and Translational Oncology Springer Milan 15/1(2013-01-01), 9-19 1699-048X 15:1<9 2013 15 12094 https://doi.org/10.1007/s12094-012-0934-8 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0934-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Sanz-Granda Ángel Weber Economía y Salud, Pharmacoeconomics Department, Madrid, Spain aut NATIONALLICENCE 700 1- Hidalgo Álvaro Universidad de Castilla-La Mancha, Las Norias 123, Majadahonda, 28221, Madrid, Spain aut NATIONALLICENCE 700 1- del Llano Juan Gaspar Casal Foundation, Madrid, Spain aut NATIONALLICENCE 700 1- Rovira Joan Universidad de Barcelona, Barcelona, Spain aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/1(2013-01-01), 9-19 1699-048X 15:1<9 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer